NCT03985852: BRIDGE

Broadening the Reach, Impact, and Delivery of Genetic Services

Completed NA Results posted Last updated 22 September 2025

What this trial tests

NA trial testing Patient Directed Standard of Care in Cancer in 3,073 participants. Completed in 31 August 2024.

Timeline

19 February 2020

Primary endpoint
31 August 2023

31 August 2024

Quick facts

Lead sponsor	University of Utah
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	other
Enrollment	3,073
Start date	19 February 2020
Primary completion	31 August 2023
Estimated completion	31 August 2024
Sites	2 locations across United States

Drugs / interventions tested

• Patient Directed Standard of Care

Conditions studied

• Cancer — all drugs for Cancer →
• Risk Reduction Behavior — all drugs for Risk Reduction Behavior →

Sponsor

University of Utah

Who can join

Adults 25 to 60, any sex, with Cancer or Risk Reduction Behavior. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Completion of Genetic Testing From Electronic Health Record Primary · 1 month following pre-test genetic counseling

Percentage of patients who decide to receive genetic testing

Group	Value	95% CI
Patient Directed Standard of Care	191
Enhanced Standard of Care	206

Completion of Pre-test Genetic Counseling From Electronic Health Record Secondary · 1 month after study invitation

Percentage of patients who decide to receive pre-test genetic counseling

Group	Value	95% CI
Patient Directed Standard of Care	400
Enhanced Standard of Care	361

Adherence to Colonoscopy: Questionnaire Secondary · 8 weeks and 13 months from pre-test counseling

Adherence to colonoscopy: questionnaire data

Group	Value	95% CI
Patient Directed Standard of Care	17
Enhanced Standard of Care	24

Sponsor's own description

The purpose of this study is to compare the uptake of genetic testing among patients randomized with two different models of genetic services delivery (a patient-directed model and an enhanced standard of care model) and examine whether the impact on uptake differs by race/ethnicity and rurality. This study will also compare the effect of these delivery models on adherence to cancer prevention and screening recommendations and other patient responses.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Uptake of Cancer Genetic Services for Chatbot vs Standard-of-Care Delivery Models: The BRIDGE Randomized Clinical Trial.
   Kaphingst KA, Kohlmann WK, Lorenz Chambers R, Bather JR, et al · · 2024 · cited 33× · PMID 39250153 · DOI 10.1001/jamanetworkopen.2024.32143
2. Comparing models of delivery for cancer genetics services among patients receiving primary care who meet criteria for genetic evaluation in two healthcare systems: BRIDGE randomized controlled trial.
   Kaphingst KA, Kohlmann W, Chambers RL, Goodman MS, et al · · 2021 · cited 31× · PMID 34078380 · DOI 10.1186/s12913-021-06489-y
3. Social vulnerability and genetic service utilization among unaffected BRIDGE trial patients with inherited cancer susceptibility.
   Bather JR, Goodman MS, Harris A, Del Fiol G, et al · · 2025 · cited 4× · PMID 39891096 · DOI 10.1186/s12885-025-13495-4